摘要
目的研究T型钙通道Cav3.1、Cav3.2蛋自在宫颈癌患者中的阳性表达率及其与宫颈癌临床病理学特征的关系。方法将2012年6月—2014年12月行子宫切除术并经病理学检查确诊为宫颈癌患者74例作为宫颈癌组,同期因子宫肌瘤进行子宫切除术患者74例作为对照组,采用SP免疫组化染色对手术切除标本进行染色,观察2组患者T型钙通道Cav3.1、Cav3.2蛋白的阳性表达率及其与宫颈癌Cav3.1、Cav3.2蛋白过表达率与临床病理特征的关系。结果宫颈癌组Cav3.1及Cav3.2的阳性表达率(94.59%、90.54%)均明显高于对照组(12.16%、14.86%),差异有统计学意义(x^2=101.029、85.005,P<0.01);Cav3.1、Cav3.2蛋白表达与患者年龄、病程、病理分型、肿瘤大小无关(Cav3.1:x^2=2.381、1.782、0.982、0.338,P>0.05;Cav3.2:0.773、0.673、0.862、0.762,P>0.05);与临床分期、细胞分化程度、淋巴结转移有关(Cav3.1:x^2=5.336、6.772、16.882,P<0.01;Cav3.2:10.934、12.762、6.542,P<0.01)。结论宫颈癌患者T-型钙通道Cav3.1、Cav3.2表达增高,T型钙通道Cav3.1、Cav3.2蛋白可能成为宫颈癌的治疗靶点及肿瘤检测的分子生物学标记物。
Objective To explore the expressions of T type Ca-(2+) channels Cav3.1 and Cav3.2 in cervical cancer and the relationships with clinical and pathological characteristics.Methods From June 2012 to December 2014,74 cases of patients,according to hysterectomy and pathologically diagnosed cervical cancer were enrolled a the cancer group,same period,74 patients with internal uterine fibroids and received hysterectomy enrolled as the control group,specimens taken from surgery were stained with the SP immunity staining in the two groups to observe the relationship between T-tvpe calcium channel Cav3.1,Cav3.2 positive expression,and their relationship with clinicopathological features.Results Cervical cancer' s positive expression rate of Cav3.1 and Cav3.2(94.59%,90.54%) were significantly higher than control group(12.16%,14.86%),the difference was statistically significant(x-2= 101.029,x-2=85.005,P〈0.01);Cav3.1,Cav3.2 protein expression did not related to patient age,duration,pathological type,tumor size(Cav3.1:x-2=2.381,x-2= 1.782,x-2 = 0.982,x-2 =0.338,P〈0.05;Gav3.2:x-2= 0.773,x-2=0.673.x-2=0.862,x-2=0.762,P〈0.05);hut correlated to clinical stage,cell differentiation,lymph node metastasis(Cav3.1:x-2= 5.336,x-2=6.772,x-2= 16.882,P〈0.01;Cav3.2:x-2= 10.934,x-2 =12.762,x-2=6.542,P〈0.01).Conclusion The expression of Cav3.1 and Cav3.2 in cervical cancer patients were increased,and the expression of T type Ca-(2+) channels Cav3.1 and Cav3.2 might be a therapeutic target for cervical cancer and molecular markers lor tumor detection.
出处
《疑难病杂志》
CAS
2015年第12期1273-1276,F0003,共5页
Chinese Journal of Difficult and Complicated Cases